RxDoctor Payments DataLook up a doctor →

Anthony Bucolo

Hematology & Oncology · Little Rock, ARNPI 1497752638

Payments from drug & device makers

$8,845in general payments, 2019–2025

Across 519 payments — averaging $17.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$796
  • Novartis$677
  • AstraZeneca$638
  • Lilly USA, LLC$553
  • Seagen Inc.$520
  • Johnson & Johnson$518
  • plus $5K from 44 others

What the payments were for

  • Food & beverage$8,23893%
  • Education$6067%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck47$796
Novartis47$677
AstraZeneca33$638
Lilly USA, LLC22$553
Seagen Inc.32$520
Johnson & Johnson(2 entities)23$518
Bristol Myers Squibb42$481
Pfizer29$442
Incyte Corporation18$349
Beigene USA, Inc.16$288
Sanofi14$255
Genentech USA, Inc.22$236
Exelixis Inc.15$202
E.r. Squibb & Sons, L.L.C.13$182
Astellas Pharma US Inc8$145
Amgen8$142
Bayer7$132
Gilead(2 entities)8$131
Karyopharm Therapeutics Inc.8$125
Alnylam Pharmaceuticals Inc.7$124
Eisai Inc.6$123
EMD Serono, Inc.7$123
Pharmacyclics LLC, An Abbvie Company7$118
Rigel Pharmaceuticals, Inc.7$117
AbbVie5$107
AVEO Pharmaceuticals, Inc.5$103
Sanofi-aventis U.S. LLC1$100
Pharmaessentia USA Corporation5$90
Ipsen Biopharmaceuticals, Inc5$86
Intuitive Surgical1$77
Array Biopharma Inc8$76
Boehringer Ingelheim3$72
Sobi, Inc3$63
G1 Therapeutics, Inc.4$58
AMAG Pharmaceuticals, Inc.3$53
Mirati Therapeutics, Inc.3$52
Regeneron Healthcare Solutions, Inc.3$51
Adaptive Biotechnologies Corporation2$50
Epizyme, Inc.3$46
Takeda Pharmaceuticals U.S.A., Inc.2$44
ADC Therapeutics America, Inc.2$39
Puma Biotechnology, Inc.2$38
Acceleron Pharma, Inc.2$35
GSK2$33
Kyowa Kirin, Inc.2$32
Servier Pharmaceuticals LLC2$31
Stemline Therapeutics Inc.2$29
Morphosys, US Inc.1$24
Daiichi Sankyo Inc.1$20
Pharmacosmos Therapeutics Inc.1$20

How this compares

$8,845 in reported general payments places this provider in the 55th percentile of 92 hematology & oncology providers in Arkansas.

See all hematology & oncology providers in Arkansas →

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban11$9,197
ClopidogrelClopidogrel Bisulfate11$157
Rosuvastatin Calcium11$156
Levothyroxine Sodium14$137
Finasteride15$133
Pantoprazole Sodium12$37

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$442$9,19711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 92 hematology & oncology providers in Arkansas.

Other hematology & oncology in Little Rock

See the full list for Arkansas →

Where these figures come from

Is this you, or does something look wrong? →